The study involved 560 adults, including 240 over the age of 70.
The data were based on earlier, Phase Two human trials of the vaccine.
The study comes a day after Pfizer-BioNTech said, their vaccine showed 95 percent efficacy from late stage Phase III trials, which was consistent across age, gender and race.
An Oxford researcher wrote in a statement that inducing robust immune responses in older adults has been a long-standing challenge.
"The next step", he said, "will be to see if this translates into protection from the disease itself". Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca.
Pollard's comments came after data published on Thursday showed the Oxford/AstraZeneca vaccine in Phase II studies produced a strong immune response in older adults.
Chinese companies Sinovac and Sinopharm are in the late stages of testing vaccines, putting them among almost a dozen companies at or near that level of development. "We're obviously not going to rush that".
Researchers say their findings are promising as they show that older people are showing a similar immune response to younger adults.
A number of studies have shown that a decreasing immune function caused by ageing results in a decreased immune response to vaccines, with this response previously observed for vaccines for influenza and hepatitis B.
The health minister pointed out that the administering of the COVID-19 vaccines would be done on the basis of scientific data.
"We set ourselves the task of ensuring the immunization of as many people as possible with tested, high-quality and safe vaccines in 2021, both through global initiatives and funds from the state budget of Ukraine", Liashko stressed. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.:17.
The most common side effects were pain at the injection site, fatigue, headache, feverishness and muscle pain.